Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Dec 18, 2008

Premium
Title: Oligonucleotide Inhibitors of MBD2/DNA Demethylase and Uses Thereof
 
Number: 7,465,714
 
Filed: June 20, 2003 PCT Filed: June 20, 2003
 
Lead Inventor: Moshe Szyf, McGill University
 
The patent, its abstract states, claims “oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase. … The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumor cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target genes for cancer therapy or diagnosis using the oligonucleotide inhibitors are also provided.”
 

 
Title: Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies
 
Number: 20080305073
 
Filed: July 4, 2005 PCT Filed: July 4, 2005
 
Lead Inventor: Domenico Barone, Creabilis Therapeutics
 
The invention, the patent application’s abstract states, “relates to the use of synthetic double-stranded nucleic acid or nucleic acid analogue molecules with a bent shape structure for the prevention and treatment of pathologies induced directly or indirectly by the HMGB1 protein.”
 

 
Title: Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
 
Number: 20080305102
 
Filed: June 23, 2006 PCT Filed: June 23, 2006
 
Lead Inventor: Toshihiro Nakajima, Saint Marianna University School of Medicine
 
“Inhibition of synoviolin function was found to activate the cancer-suppressing protein p53,” the patent application’s abstract states. “Substances inhibiting the function of synoviolin are useful as cancer therapeutic agents. The inhibition of synoviolin function was also found to lead to the inhibition of p53 ubiquitination, increased activity of p53 phosphorylation proteins, and the like. Based on these findings, the … invention provides methods capable of efficiently screening for cancer therapeutic agents,” the abstract notes.
 
“Further, it was also found that regulation of the autoubiquitination of synoviolin protein suppresses the proliferation of rheumatoid arthritis synovial cells,” it adds. “Substances regulating the autoubiquitination of synoviolin protein are useful as anti-rheumatic agents. Moreover, the … invention provides methods of efficiently screening for anti-rheumatic agents.”
 

 
Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference
 
Number: 20080305543
 
Filed: Feb. 22, 2007
 
Lead Inventor: Craig Mello, University of Massachusetts Medical School
 
“Genes involved in double-stranded RNA interference are identified and used to investigate the RNAi pathway,” the patent application’s abstract states. “The genes and their products are also useful for modulating RNAi pathway activity.”
 

 
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers
 
Number: 20080306006
 
Filed: Jan. 3, 2007 PCT Filed: Jan. 3, 2007
 
Lead Inventor: Carlo Croce, Ohio State University
 
According to the patent application’s abstract, the invention “provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.”
 

 
Title: Agents, Compositions, and Methods for Treating Pathologies in Which Regulating an AChE-Associated Biological Pathway is Beneficial
 
Number: 20080306014
 
Filed: March 7, 2007
 
Lead Inventor: Hermona Soreq, Yissum Research Development Company of the Hebrew University of Jerusalem
 
The invention, the patent application’s abstract states, “provides agents which are capable of regulating the function of a microRNA component which can be used to regulate an AChE-associated biological pathway. In addition, the … invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis, aberrant cholinergic signaling, abnormal hematopoietic proliferation and/or differentiation, cellular stress, exposure to inflammatory response-inducing agents, and/or exposure to organophosphates or other AChE inhibitors.”
 

 
Title: siRNA Targeting Proprotein Convertase Subtilisin/Kexin Type 9
 
Number: 20080306015
 
Filed: July 25, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PCSK9.”
 

 
Title: Nucleic Acid-Functionalized Nanoparticles for Therapeutic Applications
 
Number: 20080306016
 
Filed: May 30, 2008
 
Lead Inventor: Chad Mirkin, Northwestern University
 
The patent application, its abstract states, claims “materials and methods for modulating cellular uptake of functionalized nanoparticles … [as well as] materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.”
 

 
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer
 
Number: 20080306017
 
Filed: Jan. 3, 2007 PCT Filed: Jan. 3, 2007
 
Lead Inventor: Carlo Croce, Ohio State University
 
The invention claims “novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer … [as well as] methods of identifying anti-lung cancer agents,” the patent application’s abstract states.
 

 
Title: microRNA-Expression Abnormalities of Pancreatic, Endocrine, and Acinar Tumors
 
Number: 20080306018
 
Filed: Jan. 3, 2007 PCT Filed: Jan. 3, 2007
 
Lead Inventor: Carlo Croce, Ohio State University
 

The invention, the patent application’s abstract states, claims “novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer … [in addition to] methods of identifying anti-pancreatic cancer agent.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.